Fig. 4From: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancerROC AUC for circN4BP2L2, CA125, HE4 and the combination (circN4BP2L2, CA125, and HE4) in pre-menopausal EOC compared to those in pre-menopausal benign (A) and normal (B) cohorts. ROC AUC for circN4BP2L2, CA125, HE4 and the combination (circN4BP2L2, CA125, and HE4) in post-menopausal EOC compared to those in post-menopausal benign (C) and normal (D) cohortsBack to article page